drugset / Trial / NCT03941340

Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers

NCT03941340

Phase 1 Completed 6 enrolled Allist Pharmaceuticals, Inc.
NaSingle-groupOpen-labelOther

Summary

Study to Evaluate the Mass Balance and Biotransformation of Single Dose\[14C\] AST2818 in Chinese Healthy Male Volunteers

Timeline

Start
2019-04-08
Primary completion
2019-09-06
Completion
2019-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Firmonertinib Small molecule 80 mg Oral

Indications

No indication recorded.